Table I.
Demographic, baseline variables and treatment characteristics of the study population.
| Variables | RNF2 (n=83) (%) | P-AKT (n=85) (%) | RNF2/P-AKT (n=80) (%) |
|---|---|---|---|
| Sex | |||
| Male | 51 (61.4) | 53 (62.4) | 49 (61.2) |
| Female | 32 (38.6) | 32 (37.6) | 31 (38.8) |
| Age (years) | |||
| ≤66 | 44 (53.0) | 45 (52.9) | 43 (53.8) |
| >66 | 39 (47.0) | 40 (47.1) | 37 (46.3) |
| Tumor location | |||
| Cervical | 6 (7.2) | 6 (7.1) | 6 (7.5) |
| Upper thoracic | 24 (28.9) | 25 (29.4) | 24 (30.0) |
| Middle thoracic | 37 (44.6) | 38 (44.7) | 34 (42.5) |
| Lower thoracic | 16 (19.3) | 16 (18.8) | 16 (20.0) |
| Tumor length (cm) | |||
| ≤3 | 4 (4.8) | 4 (4.7) | 4 (5.0) |
| 3–5 | 33 (39.8) | 33 (38.8) | 32 (40.0) |
| 5–7 | 24 (28.9) | 25 (29.4) | 23 (28.8) |
| >7 | 22 (26.5) | 23 (27.1) | 21 (26.3) |
| Tumor volume (cm3) | |||
| ≤25 | 25 (30.1) | 26 (30.6) | 24 (30.0) |
| >25 | 58 (69.9) | 59 (69.4) | 56 (70.0) |
| T stage | |||
| 1+2 | 29 (34.9) | 29 (34.1) | 27 (33.8) |
| 3+4 | 54 (65.1) | 56 (65.9) | 53 (66.3) |
| N stage | |||
| 0 | 34 (41.0) | 35 (41.2) | 33 (41.3) |
| + | 49 (59.0) | 50 (58.8) | 47 (58.8) |
| Tumor- | |||
| Node-Metastasis stage (17) | |||
| I+II | 36 (43.4) | 37 (43.5) | 34 (42.5) |
| III+IV | 47 (56.6) | 48 (56.5) | 46 (57.5) |
| Radiation field | |||
| IFI | 45 (54.2) | 46 (54.1) | 43 (53.8) |
| ENI | 38 (45.8) | 39 (45.9) | 37 (46.3) |
| Radiation dose (Gy) | |||
| ≤60 | 42 (50.6) | 43 (50.6) | 40 (50.0) |
| >60 | 41 (49.4) | 42 (49.4) | 40 (50.0) |
| Chemotherapy | |||
| No | 41 (49.4) | 43 (50.6) | 38 (47.5) |
| Yes | 42 (50.6) | 42 (49.4) | 42 (52.5) |
RNF2, Ring finger protein 2; P-AKT, phosphor-protein kinase B; IFI, involved field radiation; ENI, elective nodal irradiation.